PPARG sirna

PPARG siRNA (Human)

Cat. Num. AAA8230229

• Gene Names: PPARG; GLM1; CIMT1; NR1C3; PPARG1; PPARG2; PPARgamma
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: PPARG; PPARG siRNA (Human); NR1C3; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3; PPARG sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: PPARG siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 477

• Applicable Applications for PPARG sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PPARG gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for PPARG sirna

siRNA to inhibit PPARG expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 116284368
• NCBI GeneID: 5468
• NCBI Accession #: NP_005028.4
• NCBI GenBank Nucleotide #: NM_005037.5
• UniProt Accession #: P37231; O00684; O00710; O14515; Q0QJH8; Q15178; Q15179; Q15180; Q15832; Q86U60; A8K3G6; B5BUA1
• Molecular Weight: 21,580 Da
• NCBI Official Full Name: peroxisome proliferator-activated receptor gamma isoform 1
• NCBI Official Synonym Full Names: peroxisome proliferator-activated receptor gamma
• NCBI Official Symbol: PPARG
• NCBI Official Synonym Symbols: GLM1; CIMT1; NR1C3; PPARG1; PPARG2; PPARgamma
• NCBI Protein Information: peroxisome proliferator-activated receptor gamma
• UniProt Protein Name: Peroxisome proliferator-activated receptor gamma
• Protein Family: Peroxisome proliferator-activated receptor
• UniProt Gene Name: PPARG
• UniProt Synonym Gene Names: NR1C3; PPAR-gamma
• UniProt Entry Name: PPARG_HUMAN

NCBI Description

This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

Uniprot Description

PPAR-gamma: a transcription factor, member of the nuclear hormone receptor superfamily. Receptor for hypolipidemic drugs and fatty acids. Preferentially expressed in adipocytes as well as in vascular smooth muscle cells and macrophage. Regulator of adipogenesis and lipid metabolism, modulates insulin sensitivity, cell proliferation and inflammation. Phosphorylated and inhibited by MAP kinase. Heterodimerizes with the retinoid X receptor. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Two splice-variant isoforms have been described.

Protein type: Nuclear receptor; DNA-binding

Chromosomal Location of Human Ortholog: 3p25

Cellular Component: nucleoplasm; perinuclear region of cytoplasm; nucleus; cytosol

Molecular Function: ligand-dependent nuclear receptor activity; transcription activator binding; zinc ion binding; drug binding; alpha-actinin binding; protein phosphatase binding; retinoid X receptor binding; arachidonic acid binding; protein binding; enzyme binding; DNA binding; ligand-dependent nuclear receptor transcription coactivator activity; prostaglandin receptor activity; sequence-specific DNA binding; steroid hormone receptor activity; estrogen receptor binding; chromatin binding; transcription factor activity

Biological Process: positive regulation of transcription, DNA-dependent; negative regulation of collagen biosynthetic process; heart development; cell maturation; rhythmic process; lipid homeostasis; response to lipid; glucose homeostasis; response to vitamin A; response to caffeine; positive regulation of oligodendrocyte differentiation; placenta development; long-chain fatty acid transport; organ regeneration; cell fate commitment; monocyte differentiation; negative regulation of acute inflammatory response; regulation of circadian rhythm; response to starvation; negative regulation of telomerase activity; cellular response to insulin stimulus; response to estrogen stimulus; lipoprotein transport; response to mechanical stimulus; brown fat cell differentiation; positive regulation of fat cell differentiation; fatty acid oxidation; steroid hormone mediated signaling; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription factor activity; negative regulation of transcription, DNA-dependent; positive regulation of phagocytosis, engulfment; negative regulation of smooth muscle cell proliferation; low-density lipoprotein receptor biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; signal transduction; epithelial cell differentiation; regulation of blood pressure; response to nutrient; caspase activation; transcription initiation from RNA polymerase II promoter; response to retinoic acid; G-protein coupled receptor protein signaling pathway; response to low density lipoprotein stimulus; white fat cell differentiation; positive regulation of fatty acid oxidation; innate immune response; gene expression; lipid metabolic process; negative regulation of cell growth; response to cold

Disease: Obesity; Lipodystrophy, Familial Partial, Type 3; Carotid Intimal Medial Thickness 1; Diabetes Mellitus, Noninsulin-dependent